Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C

Journal of Medical Virology

Volumn 81, Issue 9, 2009, Pages 1584-1590

  Arase, Yasuji ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Hirakawa, Miharu ^a   Saito, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a   Kobayashi, Tetsuro ^b  

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

A retrospective cohort study; Hepatitis C virus; Hypertension; Losartan; Type 2 diabetes mellitus

Indexed keywords

LOSARTAN; SPIRONOLACTONE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DIZZINESS; FATTY LIVER; FEMALE; FOLLOW UP; GYNECOMASTIA; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; JAPANESE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT DURATION;

AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; LOSARTAN; MALE; MIDDLE AGED; SPIRONOLACTONE;

HEPATITIS C VIRUS;

EID: 68949163165     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21572     Document Type: Article

References (29)

1. Alderman MH. 2008. New onset diabetes during antihypertensive therapy. Am J Hypertens 21:493-499.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. 1992. The natural history of community acquired hepatitis C in the United States. N Engl J Med 327:1899-1905. (Pubitemid 23006964)
3. Ando K, Fujita T. 2006. Anti-diabetic effect of blockade of the reninangiotensin system. Diabetes Obes Metab 8:396-403. (Pubitemid 44349231)
4. Arao M, Murase K,KusakabeA, YoshiokaK, Fukuzawa Y, Ishikawa T, Tagaya T, Yamanouchi K, Ichimiya H, Sameshima Y, Kakumu S. 2003. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 38: 355-360. (Pubitemid 36626271)
5. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. 2009. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49:739-744.
6. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. 2005. PPARgammaactivating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46:137-143. (Pubitemid 40946504)
7. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):Arandomised trial against atenolol. Lancet 359:995-1003. (Pubitemid 34286536)
8. Desmet VJ, Gerber M, Hoofnagle JH. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520. (Pubitemid 24166476)
9. Fleming TR, Harrington DP, O'Brien PC. 1984. Designs for group sequential tests. Control Clin Trials 5:348-361.
10. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. 1998. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 46:467-471. (Pubitemid 28484734)
11. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. 2003. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167. (Pubitemid 36928953)
12. Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M. 1995. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 8:353-357.
13. Ikeda K, Saitoh S, Koida I,Arase Y, Tsubota A,Chayama K,Kumada H, Kawanishi M. 1993. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47-53. (Pubitemid 23193616)
14. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. 2008. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: Comparison with hepatitis B virusinfected and hepatitis C virus-cleared patients. Liver Int 28:355-362. (Pubitemid 351279583)
15. Iyer SN, Katovich MJ. 1996. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructosefed rats. Am J Hypertens 9:662-668.
16. Kiyosawa K, Furuta S. 1991. Review of hepatitis C in Japan. J Gastroenterol Hepatol 6:383-391.
17. Lindholm LH, Ibsen H, Dahlö f B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:1004-1010.
18. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, NetskiD, Coresh J, SzkloM, Thomas DL. 2003.Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50-56. (Pubitemid 36775795)
19. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD. 2009. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 83:106-116.
20. Nishimura H, Sanaka T, Tanihata Y, Naito T, Higuchi C, Otsuka K. 2008. Losartan elevates the serum high-molecular weightadiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 31: 1611-1618.
21. Romero-Gómez M. 2006. Insulin resistance and hepatitis C. World J Gastroenterol 12:7075-7080.
22. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Solá R, Pons JA, Salmerón J, Barcena R, Perez R, Carmona I, Durán S. 2008. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 48:721-727.
23. TeruiY, Saito T, Watanabe H, TogashiH, Kawata S,KamadaY, Sakuta S. 2002. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36:1022.
24. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H. 1993. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801. (Pubitemid 23174709)
25. Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, Isogawa A, Ohashi Y, Kadowaki T, Tsugane S, JPHC Study Group. 2005. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: A population-based prospective study in the JPHC study cohort I. Diabet Med 22: 323-331. (Pubitemid 40313861)
26. Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053. (Pubitemid 38579764)
27. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. 2007. Epidemic obesity and type 2 diabetes in Asia. Lancet 368:1681-1688.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145-153.
29. Zandbergen AA, Lamberts SW, Janssen JA, Bootsma AH. 2006. Shortterm administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. Eur J Endocrinol 155:293-296.